Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 6700
Summary
- Conditions
- Lactation
- Pregnancy
- Renal Anemia
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
This is a non-interventional, multi-centre, longitudinal observation with a defined population using a prospective cohort design to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit™ (epoetin zet...
This is a non-interventional, multi-centre, longitudinal observation with a defined population using a prospective cohort design to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit™ (epoetin zeta) administered subcutaneously in patients with renal anaemia.
Tracking Information
- NCT #
- NCT01543477
- Collaborators
- Hospira, now a wholly owned subsidiary of Pfizer
- Investigators
- Study Director: Pfizer CT.gov Call Center Pfizer
Get Well Soon